This summer, Georgia Bio welcomed three ambitious and enthusiastic interns: Isabel Veith, Rob Warren, and Maanav Karamchandani. Our interns took some time to reflect on their internships and told us about their diverse career interests—education, politics, nonprofits—and how their internships influenced their career aspirations.

Isabel Veith, Senior Biology Major at Georgia Tech

Photo of Isabel Veith

Isabel was excited to learn about the inner workings of a nonprofit. “One of the reasons I was interested in this internship was learning the administrative and marketing side of a nonprofit. I have seen how making strategic connections between people and fostering relationships can benefit a cause.” 

During her internship, Isabel gained insight into life science education. “I learned how critical education is to the industry and how inconsistent life science opportunities and resources are in some schools. Middle and high school education is the foundation for the workforce, and I never thought about how a lack of opportunities and resources at those ages could have reverberating effects on the industry. I am very passionate about giving back to future generations. I am a firm believer in leaving a place better than you found it. I would like to eventually become a professor and be able to serve in a mentor capacity to students. I think you can make major impacts in a field just by providing encouraging words and guidance to young scientists.” 

Whatever her career path, Isabel now knows the importance of connection and working together to achieve a goal. “I would like to end up working in a nonprofit, but I think with any job I take, Georgia Bio has shown me that the way you approach a job or mission is crucial. Building networks and promoting collaboration can make all the difference.”

Rob Warren, Junior International Politics Major at Washington and Lee University

Rob says he gained great knowledge of the life sciences industry during his internship at Georgia Bio. “I had the opportunity to attend the Strategic Planning meeting in June, where I learned about the future of the industry, like drug price transparency. Attending events like this allowed me to learn more about the industry overall.” 

“I got to experience the policy and advocacy side of a trade organization. I helped with various projects, including researching policy to promote that aligns with the interests of our member organizations. I also had the opportunity to work on member engagement.” 

Rob says his time at Georgia Bio introduced him to a new potential career path. “Before the internship, I had no certain direction for my career. Now, I know I want to pursue business, maybe even lobbying. Working on policy opened me up to the business/politics career possibility.” 

Outside of science, Rob has a passion for travel. “I like to travel internationally; I’m studying abroad in Prague this fall. Some of the countries I’ve visited include Argentina, Chile, Italy, France, Canada, Mexico, Belize, and Switzerland. Exploring different cultures and places is very interesting, and I try to use what I learn from my travels in my everyday life.”

Maanav Karamchandani, Junior at Lambert High School

Maanav learned how he might one day break into the life sciences industry. “Before working with Georgia Bio, I had little exposure to the life sciences industry and was not very clear as to how I would get into the field. This internship provided me with countless opportunities to meet people working in the life sciences industry as well as learn how they got there. Georgia Bio made me a part of the team and allowed me to grow.”

He feels he really made an impact during his time at Georgia Bio. “The projects I did were a part of larger ones, and the impact of my work was visible immediately. Some of the projects I worked on include the Global Health ATL social media posts, the new Georgia Bio website, and providing new ways to increase member engagement.”

Manaav’s path to achieving his career goals was clarified thanks to his time at Georgia Bio. “I now know the type of education needed for my future career. I also have a better idea as to how to reach my goals and aspirations in this field. Meeting different people in the field has also allowed me to expand my mindset and see that there are many paths to reach my ambitions.” 

Outside of his studies, Manaav has already been making an impact on the world. “I am very passionate about community service. I founded my own nonprofit, www.myjal.org, at the age of seven to provide clean drinking water to people in need across the world.” MyJal has helped provide over 300 children and adults in need clean drinking water and continues to work on new projects. “MyJal is something that I am extremely proud of.”


All three of these interns show great passion when it comes to their career goals, and it sounds like they learned a great deal during their internships at Georgia Bio! We feel lucky to have spent the summer with these students and can’t wait to see what they accomplish in the future. Georgia Bio looks forward to welcoming more interns throughout the year and next summer!

By Sheran Brown February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community
By Sheran Brown February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.
By Sheran Brown February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: